{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T16:23:19Z","timestamp":1789402999686,"version":"build-2803163510"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100005230","name":"Natural Science Foundation of Chongqing Municipality","doi-asserted-by":"publisher","award":["cstc2021jcyj-msxmX0544"],"award-info":[{"award-number":["cstc2021jcyj-msxmX0544"]}],"id":[{"id":"10.13039\/501100005230","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011476","name":"Third Military Medical University Southwest Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011476","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Immunology Letters"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.imlet.2025.107003","type":"journal-article","created":{"date-parts":[[2025,4,6]],"date-time":"2025-04-06T16:41:30Z","timestamp":1743957690000},"page":"107003","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["The immune-reinforcements of Lenvatinib plus anti-PD-1 and their rationale to unite with TACE for unresectable hepatocellular carcinoma treatment"],"prefix":"10.1016","volume":"275","author":[{"given":"Jiayun","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanjiao","family":"Ou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiejuan","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyun","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leida","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8960-5000","authenticated-orcid":false,"given":"Yu","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.imlet.2025.107003_bib0001","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1002\/onco.13566","article-title":"FDA Supplemental Approval summary: lenvatinib for the treatment of unresectable hepatocellular carcinoma","volume":"26","author":"Nair","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.imlet.2025.107003_bib0002","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/s43856-023-00390-x","article-title":"Lenvatinib activates anti-tumor immunity by suppressing immunoinhibitory infiltrates in the tumor microenvironment of advanced hepatocellular carcinoma","volume":"3","author":"Yamauchi","year":"2023","journal-title":"Commun. Med."},{"key":"10.1016\/j.imlet.2025.107003_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2020.188391","article-title":"Lenvatinib for hepatocellular carcinoma: from preclinical mechanisms to anti-cancer therapy","volume":"1874","author":"Zhao","year":"2020","journal-title":"Biochimica et Biophysica Acta (BBA) - Rev. Cancer"},{"key":"10.1016\/j.imlet.2025.107003_bib0004","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41420-021-00747-y","article-title":"Genome-scale CRISPR-Cas9 knockout screening in hepatocellular carcinoma with lenvatinib resistance","volume":"7","author":"Lu","year":"2021","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.imlet.2025.107003_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2024.104069","article-title":"New insights into the mechanism of resistance to lenvatinib and strategies for lenvatinib sensitization in hepatocellular carcinoma","author":"Fan","year":"2024","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.imlet.2025.107003_bib0006","article-title":"Immune checkpoint inhibitors in hepatocellular carcinoma: current progresses and challenges","volume":"11","author":"Liu","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.imlet.2025.107003_bib0007","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.apsb.2019.08.010","article-title":"Therapeutic strategies for the costimulatory molecule OX40 in T-cell-mediated immunity","volume":"10","author":"Fu","year":"2020","journal-title":"Acta Pharmaceut. Sinica B"},{"key":"10.1016\/j.imlet.2025.107003_bib0008","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1080\/14712598.2018.1499722","article-title":"Recent developments with immunotherapy for hepatocellular carcinoma","volume":"18","author":"Waidmann","year":"2018","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.imlet.2025.107003_bib0009","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","article-title":"Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma","volume":"76","author":"Cheng","year":"2022","journal-title":"J. Hepatol."},{"key":"10.1016\/j.imlet.2025.107003_bib0010","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus Bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn Richard","year":"2020","journal-title":"New England J. Med."},{"key":"10.1016\/j.imlet.2025.107003_bib0011","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.751159","article-title":"Lenvatinib plus Immune checkpoint inhibitors improve survival in advanced hepatocellular carcinoma: a retrospective study","volume":"11","author":"Huang","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.imlet.2025.107003_bib0012","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.1200\/JCO.20.00808","article-title":"Phase ib study of Lenvatinib plus Pembrolizumab in patients with unresectable hepatocellular carcinoma","volume":"38","author":"Finn","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.imlet.2025.107003_bib0013","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1159\/000522547","article-title":"Final results of TACTICS: a randomized, prospective trial comparing transarterial chemoembolization plus Sorafenib to transarterial chemoembolization alone in patients with unresectable hepatocellular carcinoma","volume":"11","author":"Kudo","year":"2022","journal-title":"Liver Cancer"},{"key":"10.1016\/j.imlet.2025.107003_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102622","volume":"72","author":"Jin","year":"2024","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.imlet.2025.107003_bib0015","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.874473","article-title":"Efficacy and safety of TACE combined with Lenvatinib plus PD-1 inhibitors compared with TACE alone for unresectable hepatocellular carcinoma patients: a prospective cohort study","volume":"12","author":"Qu","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.imlet.2025.107003_bib0016","doi-asserted-by":"crossref","first-page":"11513","DOI":"10.1002\/cam4.5880","article-title":"Efficacy and safety of TACE combined with lenvatinib and PD-1 inhibitors for unresectable recurrent HCC: a multicenter, retrospective study","volume":"12","author":"Wang","year":"2023","journal-title":"Cancer Med."},{"key":"10.1016\/j.imlet.2025.107003_bib0017","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1159\/000528356","article-title":"Outcomes of salvage surgery for initially unresectable hepatocellular carcinoma converted by transcatheter arterial chemoembolization combined with Lenvatinib plus Anti-PD-1 antibodies: a multicenter retrospective study","volume":"12","author":"Wu","year":"2022","journal-title":"Liver Cancer"},{"key":"10.1016\/j.imlet.2025.107003_bib0018","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003133","article-title":"Single-cell immune signature for detecting early-stage HCC and early assessing anti-PD-1 immunotherapy efficacy","volume":"10","author":"Shi","year":"2022","journal-title":"J. Immunother Cancer"},{"key":"10.1016\/j.imlet.2025.107003_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijsu.2021.106165","article-title":"STROCSS 2021: strengthening the reporting of cohort, cross-sectional and case-control studies in surgery","volume":"96","author":"Mathew","year":"2021","journal-title":"Int. J. Surg."},{"key":"10.1016\/j.imlet.2025.107003_bib0020","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1158\/2159-8290.CD-21-1022","article-title":"IFN\u03b1 potentiates anti\u2013PD-1 efficacy by remodeling glucose metabolism in the hepatocellular carcinoma microenvironment","volume":"12","author":"Hu","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.imlet.2025.107003_bib0021","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/nprot.2015.020","article-title":"Palladium-based mass tag cell barcoding with a doublet-filtering scheme and single-cell deconvolution algorithm","volume":"10","author":"Zunder","year":"2015","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.imlet.2025.107003_bib0022","doi-asserted-by":"crossref","first-page":"E5900","DOI":"10.1073\/pnas.1706559114","article-title":"Delineation of an immunosuppressive gradient in hepatocellular carcinoma using high-dimensional proteomic and transcriptomic analyses","volume":"114","author":"Chew","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"10.1016\/j.imlet.2025.107003_bib0023","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/nmeth.3863","article-title":"Automated mapping of phenotype space with single-cell data","volume":"13","author":"Samusik","year":"2016","journal-title":"Nat. Methods"},{"key":"10.1016\/j.imlet.2025.107003_bib0024","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.apmt.2019.05.007","article-title":"Single-cell mass cytometry reveals in vivo immunological response to surgical biomaterials","volume":"16","author":"Wu","year":"2019","journal-title":"Appl. Mater. Today"},{"key":"10.1016\/j.imlet.2025.107003_bib0025","doi-asserted-by":"crossref","first-page":"5040","DOI":"10.4049\/jimmunol.1001900","article-title":"Murine B cells regulate serum IgE levels in a CD23-dependent manner","volume":"185","author":"Cheng","year":"2010","journal-title":"J. Immunol."},{"key":"10.1016\/j.imlet.2025.107003_bib0026","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1038\/nri3084","article-title":"Towards a systems understanding of MHC class I and MHC class II antigen presentation","volume":"11","author":"Neefjes","year":"2011","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.imlet.2025.107003_bib0027","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/80877","article-title":"CD27 is required for generation and long-term maintenance of T cell immunity","volume":"1","author":"Hendriks","year":"2000","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.imlet.2025.107003_bib0028","doi-asserted-by":"crossref","first-page":"9105","DOI":"10.2147\/OTT.S220196","article-title":"Checkpoint CD47 function on tumor metastasis and immune therapy","volume":"12","author":"Lian","year":"2019","journal-title":"Onco. Targets Ther."},{"key":"10.1016\/j.imlet.2025.107003_bib0029","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3350\/cmh.2022.0212","article-title":"Utility of combining PIVKA-II and AFP in the surveillance and monitoring of hepatocellular carcinoma in the Asia-Pacific region","volume":"29","author":"Kim","year":"2023","journal-title":"Clin. Mol. Hepatol."},{"key":"10.1016\/j.imlet.2025.107003_bib0030","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13045-022-01282-8","article-title":"Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets","volume":"15","author":"Tie","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.imlet.2025.107003_bib0031","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1038\/s41401-022-00910-w","article-title":"Engineered nanomedicines block the PD-1\/PD-L1 axis for potentiated cancer immunotherapy","volume":"43","author":"Li","year":"2022","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.imlet.2025.107003_bib0032","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001845","article-title":"Prospective development and validation of a liquid immune profile-based signature (LIPS) to predict response of patients with recurrent\/metastatic cancer to immune checkpoint inhibitors","volume":"9","author":"Zhou","year":"2021","journal-title":"J. Immunother Cancer"},{"key":"10.1016\/j.imlet.2025.107003_bib0033","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2025.114052","article-title":"Peripheral blood PD-1(+) T lymphocytes as biomarkers in liquid biopsies for solid tumors: clinical significance and prognostic applications","volume":"147","author":"Piao","year":"2025","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.imlet.2025.107003_bib0034","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1200\/JCO.22.00392","article-title":"Lenvatinib combined with transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma: a phase III, randomized clinical trial (LAUNCH)","volume":"41","author":"Peng","year":"2022","journal-title":"J. Clin. Oncol.y"}],"container-title":["Immunology Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165247825000355?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165247825000355?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T08:12:23Z","timestamp":1748419943000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165247825000355"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":34,"alternative-id":["S0165247825000355"],"URL":"https:\/\/doi.org\/10.1016\/j.imlet.2025.107003","relation":{},"ISSN":["0165-2478"],"issn-type":[{"value":"0165-2478","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The immune-reinforcements of Lenvatinib plus anti-PD-1 and their rationale to unite with TACE for unresectable hepatocellular carcinoma treatment","name":"articletitle","label":"Article Title"},{"value":"Immunology Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.imlet.2025.107003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Federation of Immunological Societies. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107003"}}